Former Cytiva CEO Emmanuel Ligner Takes Helm at Avantor: 30-Year Industry Veteran to Drive Growth
Avantor has announced the appointment of Emmanuel Ligner as its new President and CEO, effective August 18, 2025. Ligner brings over 30 years of experience in the life sciences industry, including leadership roles at GE Life Sciences and as CEO of Cytiva and Cerba HealthCare. His appointment is expected to drive competitive growth across Avantor's Lab Solutions and Bioscience Production divisions.
Avantor Stock Fell 50% Last Year and Sits Near a 52-Week Low. Could it Recover in 2026?
Avantor (AVTR) stock plummeted 50% last year, resting near its 52-week low after reporting Q4 2025 results with an in-line EPS, a slight revenue beat, but disappointing 2026 guidance forecasting another year of organic revenue decline and lower adjusted EPS. The company faces persistent volume pressure, difficult year-over-year comparisons, and margin contraction, with a recovery heavily dependent on its "Revival" program stabilizing organic growth by year-end 2026 amid varied market conditions. While analysts' mean price target shows a potential upside, significant execution risk remains, suggesting AVTR is a "wait-and-see" stock until organic revenue improves.
A Look At Avantor (AVTR) Valuation After A Year Of Weak Shareholder Returns
Avantor (AVTR) has experienced a significant share price decline over the past year, resulting in a negative shareholder return and a low value score. Despite this, a common narrative suggests the stock is undervalued by about 43% with a fair value of $13.04, driven by growth in biologics and personalized medicine. However, potential risks like weaker bioprocessing demand and elevated leverage could challenge this undervalued thesis, prompting investors to conduct their own analysis.
Ontario Teachers Pension Plan Board Invests $3.68 Million in Avantor, Inc. $AVTR
The Ontario Teachers Pension Plan Board recently acquired a new position in Avantor, Inc. (NYSE:AVTR), purchasing 294,746 shares valued at approximately $3.68 million in Q3. This investment comes as Avantor reported beating EPS estimates and provided its FY2026 guidance, while key company directors also made significant insider stock purchases. Despite some analyst downgrades, the stock holds a consensus "Hold" rating with institutional investors owning a substantial 95.08% of the company.
Bear of the Day: Avantor (AVTR)
Avantor (AVTR) has been designated as the "Bear of the Day" by Zacks Investment Research due to its deteriorating fundamentals, including a 13% decline in annual revenue over the past four years and compressed net margins. The company faces persistent downward earnings revisions from analysts, leading to a Zacks Rank #5 (Strong Sell). Investors are advised to view AVTR as a stock to avoid until there's clear stabilization in sales trends and analyst revisions.
Hedge Fund and Insider Trading News: Bill Ackman, Ray Dalio, David Einhorn, Appaloosa Management, Brevan Howard Asset Management, Maverick Capital, Viking Global, DraftKings Inc (DKNG), Avantor Inc (AVTR), and More
This article compiles recent news in the hedge fund and insider trading world, featuring prominent figures like Bill Ackman, Ray Dalio, and David Einhorn, alongside key firms such as Appaloosa Management and Viking Global. It highlights significant activities including legal challenges for Ackman, Greenlight Capital's increased stakes, Brevan Howard's crypto fund performance, and insider buying in companies like DraftKings and Avantor. The piece also includes a recommendation for a promising AI stock that is trading at less than five times its earnings and has shown positive returns despite recent market declines.
Avantor Reports Q4 Profit, Full-Year Loss for 2025
Avantor Inc. reported a fourth-quarter 2025 net income of $52 million but a full-year net loss of $530 million, a significant drop from 2024's income. The company is implementing its "Revival program" to turn around performance and drive top-line growth, with 2026 anticipated to be a year of transition and strategic investment. Despite organic sales declines in both segments, the CEO expressed confidence that these steps will lead to sustainable shareholder value creation.
The 5 Most Interesting Analyst Questions From Avantor's Q4 Earnings Call
Avantor's Q4 2025 earnings call revealed a challenging year with revenue decline and operating margin compression, attributed to the newly launched Revival program and external pressures. Analysts raised key questions regarding growth comparisons, the conservatism of the 2026 outlook, margin impact from investments, pricing actions, and future portfolio changes. Management indicated 2026 would be a transition year focused on investment, with a prudent outlook and ongoing portfolio evaluation.
Bear of the Day: Avantor (AVTR)
Avantor (AVTR) has been identified as a "Bear of the Day" due to its deteriorating financials, including declining sales over the past four years, shrinking net margins, and persistent downward revisions in analyst earnings estimates. The company faces ongoing operational pressure and structural headwinds, leading to a Zacks Rank #5 (Strong Sell). Investors are advised to approach AVTR with caution or avoid it until there are clear signs of stabilization in sales and analyst revisions.
Avantor, Inc. $AVTR Shares Sold by Rhumbline Advisers
Rhumbline Advisers significantly reduced its stake in Avantor, Inc. (NYSE:AVTR) by 9.2% in the third quarter, selling 175,164 shares, though institutional investors still hold approximately 95% of the stock. Despite this, some insiders, including Director Sanjeev K. Mehra and Director Gregory L. Summe, have recently purchased substantial amounts of shares, increasing insider ownership to around 1.2%. Avantor reported Q3 earnings that beat estimates with an EPS of $0.22 and revenue of $1.66 billion, while analysts maintain an average "Hold" rating with a consensus target price of $11.84.
Short Interest in Avantor, Inc. (NYSE:AVTR) Expands By 25.3%
Avantor, Inc. (NYSE:AVTR) experienced a significant 25.3% increase in short interest during January, reaching 37.7 million shares, which represents about 5.6% of its outstanding shares. This rise in short interest comes alongside mixed financial results and a lowered FY2026 EPS guidance from management, despite two directors making substantial insider purchases. The stock's current trading activity and analyst ratings suggest a "Hold" consensus with a target price of $11.84.
Avantor (AVTR) PT lowered to $11 by BofA following soft FY 2026 guidance
BofA has lowered its price target for Avantor (AVTR) to $11 after the company provided soft guidance for fiscal year 2026. This adjustment reflects analyst expectations based on the company's financial outlook.
Avantor (AVTR) PT Lowered to $11 by BofA Following Soft FY 2026 Guidance
Bank of America (BofA) and Citi have both lowered their price targets for Avantor (AVTR) to $11, maintaining a Neutral rating. This decision follows Vanguard's soft FY 2026 guidance and Q4 2025 results, which fell below expectations, leading to concerns about limited visibility for recovery and continued share pressure.
Avantor (AVTR) PT Lowered to $11 by BofA Following Soft FY 2026 Guidance
Bank of America (BofA) analyst Michael Ryskin has lowered the price target for Avantor (AVTR) to $11 from $13, maintaining a Neutral rating, following the company's soft FY 2026 guidance and sharp market reaction. Citi also reduced its price target to $11 from $13 due to disappointing Q4 2025 results and FY 2026 guidance. Both firms cited limited visibility into recovery and a lack of a clear improvement path from management, suggesting continued pressure on the stock.
The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%
Avantor, Inc. (NYSE:AVTR) shares have dropped 27% in the last month, contributing to a 50% decline over the past year. The company's price-to-sales (P/S) ratio of 1x is significantly lower than the industry average, primarily due to declining revenues and a forecast for slower future growth compared to its peers. Investors appear to be reacting negatively to the company's past revenue shrinkage and its less optimistic growth outlook, suggesting that the current low P/S ratio is reflective of these concerns.
Avantor (NYSE:AVTR) Director Acquires $940,000.00 in Stock
Avantor Director Gregory Summe purchased 100,000 shares of company stock for $940,000, bringing his total stake to 400,000 shares. This insider buying comes as Avantor reported mixed Q4 earnings, beating EPS consensus but missing on revenue growth and providing lower-than-expected FY2026 guidance. The stock experienced a significant drop, and analysts maintain a "Hold" rating with an average target price of $12.09.
Avantor, Inc. (NYSE:AVTR) Q4 2025 Earnings Call Transcript
Avantor, Inc. (NYSE:AVTR) reported its Q4 2025 earnings, missing EPS expectations. The company is undergoing a "Revival" program, reorganizing into two new business units: VWR distribution and services, and bioscience and medtech products, to sharpen strategic focus and improve execution. Avantor anticipates 2026 to be a year of transition and investment, with expected organic revenue growth of -2.5% to -0.5% and adjusted EPS of 77¢ to 83¢.
The Truth About Avantor Inc: Why Wall Street Won’t Shut Up About AVTR
This article examines Avantor Inc (AVTR), a "picks-and-shovels" player in the life sciences sector, highlighting why it's gaining attention on Wall Street despite not being a mainstream consumer brand. It delves into Avantor's business model, stock performance, and positioning against competitors like Thermo Fisher Scientific, concluding that it's a "grown-up growth play" for investors interested in long-term trends in healthcare and biotech. The piece advises potential investors to consider its role in the scientific ecosystem rather than expecting meme-stock-level volatility.
The Truth About Avantor Inc: Why Wall Street Won’t Shut Up About AVTR
Avantor Inc (AVTR) is a "grown-up growth play" in the life sciences sector, supplying critical materials, equipment, and services for biopharma and healthcare. While not a viral consumer brand, it's gaining attention on financial social media for its role as a "picks-and-shovels" provider in the healthcare and biotech gold rush. Investors are considering AVTR for its long-term potential tied to the expanding life science ecosystem, despite its less "meme-worthy" profile compared to larger rivals like Thermo Fisher Scientific.
UBS Cuts Avantor Price Target to $10.50 From $13, Maintains Neutral Rating
UBS has lowered its price target for Avantor (AVTR) shares to $10.50 from $13, while reiterating a Neutral rating on the stock. This adjustment reflects a modified outlook for the life science tools company. The news follows other recent analyst downgrades and a period of falling shares after Avantor's Q4 and full-year 2025 earnings report.
AVTR Stock Plunges Despite Q4 Earnings Beat Estimates, Margins Decline
Avantor, Inc. (AVTR) reported a Q4 2025 adjusted EPS of 22 cents and revenues of $1.66 billion, both surpassing Zacks Consensus Estimates. Despite the beat, the company's stock plunged due to a year-over-year decline in both earnings and revenues, and significant margin contraction. Avantor provided a cautious outlook for 2026, anticipating negative organic revenue growth and continued margin pressure, as it embarks on a "Revival" initiative to stabilize the business.
Avantor, Inc. (AVTR) Surpasses Q4 Earnings and Revenue Estimates
Avantor, Inc. (AVTR) reported Q4 earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.21, although lower than the $0.27 per share from a year ago. The company also surpassed revenue estimates, posting $1.66 billion against an expected $1.61 billion. Despite outperforming estimates, Avantor's shares have declined 2.6% year-to-date, contrasting with the S&P 500's gain.
Avantor (NYSE:AVTR) Surprises With Q4 CY2025 Sales But Stock Drops
Avantor (NYSE:AVTR) reported Q4 CY2025 results, with sales exceeding market expectations at $1.66 billion, a 1.4% year-on-year decline, and adjusted EPS in line with estimates at $0.22. Despite beating revenue estimates, the stock dropped due to a decline in operating margin and flat EPS over the last five years, indicating challenges with profitability and consistent growth. The company is undergoing a "Revival program" to improve agility and strategic focus.
Avantor Inc (AVTR) Stock Price, Quote, News & History
Avantor Inc.'s stock (AVTR) fell significantly after its Q4 2025 earnings release, which included soft guidance for 2026 and a projected revenue decline. The CEO outlined an investment year and a turnaround plan, acknowledging margin pressures. Analyst consensus indicates a "Hold" rating with a price target of $18.14, while the stock currently trades at $9.64.
Avantor reports Q4 sales decline as “Revival” turnaround begins
Avantor, Inc. (NYSE: AVTR) announced a decline in fourth-quarter revenue and provided a cautious outlook for 2026. The life sciences supplier has launched a "Revival" program to overhaul its manufacturing, supply chain, and digital channels, aiming for long-term shareholder value creation despite anticipated continued headwinds in 2026. Both the Laboratory Solutions and Bioscience Production segments experienced organic declines during the quarter.
Avantor Inc stock hits 52-week low at $8.90
Avantor Inc. (AVTR) stock has fallen to a new 52-week low of $8.90, representing a 38.17% decrease over the past year. This decline follows the company's Q4 2025 financial results, where it met EPS expectations but surpassed revenue forecasts with $1.66 billion. Despite positive financial figures, investor concerns over future guidance and market conditions led to a stock decline.
Traders Purchase Large Volume of Put Options on Avantor (NYSE:AVTR)
Investors recently bought a significantly higher volume of put options on Avantor (NYSE:AVTR), signaling expectations of increased volatility or downside for the stock. This unusual options activity comes despite Avantor beating Q4 earnings estimates with $1.66 billion in revenue and outlining a "revival" plan to improve margins, though the company reported a full-year GAAP net loss. The stock also saw a notable insider purchase by a director, contrasting with a sharp increase in short interest, indicating mixed sentiment among investors.
Avantor shares drop more than 5% as turnaround efforts fail to excite investors
Avantor's shares dropped over 5% despite the company's efforts to reassure investors about its turnaround strategy. Analysts noted that the company's initiatives failed to generate sufficient enthusiasm, leading to the stock decline. Investors remain unconvinced by the projected timelines for margin improvement.
Avantor Q4 Earnings Call Highlights
Avantor has launched "Project Revival" to reorganize into two new reporting segments: VWR Distribution and Services, and Bioscience and Medtech Products. The company anticipates 2026 to be a transitional year with guided organic revenue growth of -2.5% to -0.5%, adjusted EPS of $0.77-$0.83, and free cash flow of $500-$550 million. Management highlighted stability in end markets after a challenging 2025, with biopharma remaining healthy and cautious optimism for early-stage biotech, education, and government sectors.
Avantor (NYSE: AVTR) reports 2025 net loss, launches Revival and new segments
Avantor (NYSE: AVTR) reported a net loss of $530 million for the full year 2025, largely due to a $785 million goodwill impairment, despite generating strong operating cash flow of $624 million. The company announced a significant segment realignment into "VWR Distribution & Services" and "Bioscience & Medtech Products," effective Q1 2026, and is launching a "Revival" program to enhance performance. Net sales for 2025 were $6.55 billion, a 3.4% decrease year-over-year, with both Laboratory Solutions and Bioscience Production segments experiencing organic declines.
Avantor, Inc. SEC 10-K Report
Avantor, Inc. has released its annual 10-K report, detailing a decline in net sales, gross profit, and operating income due to divestitures, reduced demand, and inflationary pressures. Despite these financial challenges, the company is implementing a global cost transformation initiative expected to generate significant savings and is focusing on innovation and customer engagement in emerging scientific areas. The report also highlights various risks, including market competition, operational interruptions, and cybersecurity threats, while outlining strategic capital management actions like debt refinancing and a share repurchase program.
Avantor drops as 2026 outlook disappoints
Avantor's stock dropped significantly after the life sciences company provided a disappointing outlook for 2026. This occurred despite the company reporting better-than-expected revenue and in-line earnings for the fourth quarter of 2025. The firm's adjusted earnings per share projection for 2026, ranging from $0.77 to $0.83, failed to satisfy investors.
Avantor, Inc Reveals Retreat In Q4 Bottom Line
Avantor, Inc (AVTR) reported a significant decline in its fourth-quarter profit, with earnings dropping from $500.4 million to $52.4 million year-over-year. The company's adjusted earnings also saw a decrease to $0.22 per share. This financial retreat comes as Avantor's revenue for the period fell by 1.4% to $1.663 billion compared to the previous year.
Avantor, Inc. (AVTR) Surpasses Q4 Earnings and Revenue Estimates
Avantor, Inc. (AVTR) reported Q4 earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.21, and revenues of $1.66 billion, surpassing estimates by 3.00%. Despite this, the company's shares have underperformed the S&P 500 year-to-date. The stock currently holds a Zacks Rank #2 (Buy), indicating an expected outperformance in the near future based on favorable estimate revisions.
Avantor, Inc Reveals Retreat In Q4 Bottom Line
Avantor, Inc (AVTR) reported a significant retreat in its fourth-quarter profit, with earnings dropping to $52.4 million, or $0.08 per share, from $500.4 million, or $0.73 per share, in the prior year. Excluding certain items, adjusted earnings were $146 million, or $0.22 per share. The company's revenue also experienced a slight decline of 1.4%, falling to $1.663 billion from $1.686 billion year-over-year.
Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avantor, Inc. (AVTR) securities. Investors who bought Avantor shares before March 5, 2024, and still hold them, are encouraged to contact the firm to assist with the investigation into potential corporate wrongdoing by Avantor and its officers/directors. The firm operates on a contingency fee basis, meaning investors incur no out-of-pocket expenses unless the firm is successful.
AVTR Avantor NYSE -0.62% after-hours 10 Feb 2026: earnings may set the next trading range
Avantor, Inc. (AVTR) shares are trading at USD 11.16 after-hours as the company prepares to release its earnings report on February 11, 2026. Analysts anticipate adjusted EPS around USD 0.22 and a 2.9% year-over-year revenue decrease. While Wall Street's consensus target is USD 13.60, Meyka AI's model projects a lower 12-month value of USD 6.44, indicating potential downside.
Avantor Q4 2025 earnings preview
This article provides an earnings preview for Avantor's Q4 2025 financial results. It indicates the stock's recent performance and the consensus expectations for earnings per share and revenue.
Bessemer Group Inc. Sells 7,001,679 Shares of Avantor, Inc. $AVTR
Bessemer Group Inc. significantly reduced its stake in Avantor, Inc. (NYSE:AVTR) by 98.7% in the third quarter, selling over 7 million shares and retaining 93,783 shares valued at approximately $1.17 million. Despite this substantial sell-off, Avantor's director, Sanjeev K. Mehra, bought 350,000 shares in early December, increasing his direct ownership. The company currently trades around $11.25, with institutional ownership at about 95% and analysts holding a consensus "Hold" rating with an average target price of $13.60.
Avantor (AVTR) Reports Q4: Everything You Need To Know Ahead Of Earnings
Avantor (AVTR) is set to announce its Q4 earnings results on Wednesday. Analysts expect Avantor's revenue to decrease by 2.9% year-on-year to $1.64 billion, with adjusted earnings around $0.22 per share. The company has a history of missing Wall Street's revenue estimates and its stock has underperformed the research tools & consumables segment recently.
Avantor (AVTR) Projected to Post Earnings on Wednesday
Avantor (AVTR) is expected to report its Q4 2025 earnings before market open on Wednesday, February 11th, with analysts forecasting an EPS of $0.21 on $1.6359 billion in revenue. The stock currently has a "Hold" rating from analysts with an average price target of $13.60. Insider transactions show Director Sanjeev K. Mehra recently purchased 350,000 shares, bringing insider ownership to 1.20% while institutional investors hold approximately 95% of the stock.
Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026
Avantor, Inc. (NYSE: AVTR) announced it will release its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026, before the market opens. A conference call to discuss these results will be held on the same day at 8:00 a.m. Eastern Standard Time, with a live audio webcast available through the investor section of Avantor's website. Avantor is a leading global provider of mission-critical products and services in the life sciences and advanced technology industries.
Thrivent Financial for Lutherans Increases Stake in Avantor, Inc. $AVTR
Thrivent Financial for Lutherans significantly increased its stake in Avantor, Inc. (NYSE:AVTR) by 6.7% in the third quarter, now owning 2,828,696 shares valued at approximately $35.3 million. Additionally, Avantor Director Sanjeev K. Mehra acquired 350,000 shares for about $3.88 million. The company currently holds a "Hold" consensus rating from analysts with a target price of $13.60.
Strs Ohio Sells 579,993 Shares of Avantor, Inc. $AVTR
Strs Ohio significantly reduced its stake in Avantor, Inc. by 97.3% in the third quarter, selling 579,993 shares and now holding only 15,797 shares. Despite this large sell-off by Strs Ohio, other institutional investors have altered their positions, with some increasing their holdings. Insider activity shows Director Sanjeev K. Mehra recently acquired 350,000 shares, and Wall Street analysts currently have a consensus "Hold" rating for Avantor with an average price target of $13.60.
Greenhaven Associates Inc. Invests $228.53 Million in Avantor, Inc. $AVTR
Greenhaven Associates Inc. has acquired a significant new stake in Avantor, Inc. (NYSE:AVTR), purchasing over 18 million shares valued at approximately $228.53 million, making it their 8th largest position. This investment now represents about 2.69% of Avantor's total holdings for Greenhaven. The article also notes recent insider buying by Director Sanjeev K. Mehra and provides an overview of analyst ratings and Avantor's recent financial performance.
(AVTR) Movement as an Input in Quant Signal Sets
This article analyzes Avantor Inc. (NASDAQ: AVTR) using quantitative signals, highlighting weak sentiment across all horizons supporting a short bias. It details exceptional risk-reward setups and outlines three distinct AI-generated trading strategies: Position Trading (Long), Momentum Breakout (Long), and Risk Hedging (Short). The analysis includes multi-timeframe signal strengths, support, and resistance levels for AVTR.
Great Lakes Advisors LLC Sells 201,607 Shares of Avantor, Inc. $AVTR
Great Lakes Advisors LLC reduced its stake in Avantor, Inc. by 15.8% in the third quarter, selling over 200,000 shares but retaining a significant holding valued at about $13.43 million. Despite this, other institutional investors increased their positions, and a company director made a substantial insider purchase. Avantor, currently trading near its 52-week low, carries a "Hold" consensus rating with a target price of $13.60 amidst mixed analyst actions and a negative P/E ratio.
Avantor, Inc. (NYSE:AVTR) Given Consensus Recommendation of "Hold" by Brokerages
Avantor, Inc. (NYSE:AVTR) has received a consensus "Hold" rating from brokerages, with an average one-year price target of $13.60. This comes after several downgrades from firms like Raymond James Financial and Bank of America, and a recent miss on EPS and revenue in their last earnings report. Despite the "Hold" recommendation, an insider, Director Sanjeev K. Mehra, recently purchased 350,000 shares, increasing insider ownership to 1.20%.
Avantor, Inc. $AVTR Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in Avantor, Inc. (NYSE:AVTR) by 57.0% in Q3, selling over 216,000 shares. This comes as Avantor reported mixed Q3 earnings, missing EPS estimates and experiencing a year-over-year revenue decrease, resulting in the stock trading near its 52-week low. Despite institutional ownership being high, a director, Sanjeev Mehra, purchased 350,000 shares.
Kuehn Law Encourages Investors of Avantor, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating Avantor, Inc. (NYSE: AVTR) for potential breaches of fiduciary duties by its officers and directors. A federal securities lawsuit alleges that Avantor misrepresented its competitive position and failed to disclose increased competition, making previous statements materially false. Investors who purchased AVTR shares before March 5, 2024, are encouraged to contact Kuehn Law.
